This review focuses on the diagnosis, risk factors, prevalence, pathogenesis and treatment of pediatric nonalcoholic steatohepatitis (NASH). NASH is a progressive form of nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease in children. The factors that account for differences between children with NASH versus children with milder forms of NAFLD are unclear. The diagnosis of NASH requires interpretation of liver histology because no noninvasive markers predict the presence or severity of NASH. There is no proven treatment for NASH. Several clinical trials for NAFLD are in progress, however, clinical trials focusing on NASH are needed. Heightened physician awareness of NAFLD, NASH, and associated risk factors is important to identify and treat affected children.
Keywordscirrhosis; histology; obesity; nonalcoholic fatty liver disease; pediatric; children Nonalcoholic steatohepatitis (NASH) was first documented in children in 1983(1), and has since been recognized as a progressive form of nonalcoholic fatty liver disease (NAFLD). Liver histology in NAFLD ranges from simple steatosis, to steatosis with inflammation and cellular injury (NASH). Fibrosis, including cirrhosis, may also be present in NAFLD. NASH is included within the spectrum of NAFLD. In this review, the term 'NAFLD' is used to refer to the entire spectrum of histology, while 'NASH' refers only to the subset of NAFLD with histology consistent with NASH.NAFLD is the most common cause of chronic liver disease in American children,(2) and has been described throughout much of the world.(3-8) Children with NAFLD can have advanced fibrosis or cirrhosis.(9-11) NAFLD in children is strongly associated with metabolic syndrome, greatly increasing the potential for future cardiovascular disease and diabetes mellitus.(12) Thus the potential for adverse outcomes coupled with the high prevalence of the disease makes for a considerable public health concern. Recent studies indicate that NAFLD is under-© 2009 Elsevier Inc. All rights reserved.Correspondence: Jeffrey B. Schwimmer, M.D., Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103-8450, e-mail: jschwimmer@ucsd.edu, phone: 619-543-7544, fax: 619-543-7537. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. (13,14) indicating a need to heighten physician awareness of this disease.
NIH Public AccessIn the past 4 years, many reviews have described NAFLD in children;(15-21) however, these have not focused on NASH. Children with...